Dr. Henry Fisher holds a PhD from Oxford University in CNS drug delivery. He began his career at the Beckley Foundation in 2015 and has since founded three companies in the psychedelics and cannabis sectors. His work has primarily focused on R&D strategy, intellectual property generation, regulatory submissions and research operations. At Clerkenwell Health, Dr. Fisher has led engagements with key regulatory bodies, including the MHRA and FDA, as well as overseeing Schedule 1 drug license applications.

Balancing Scientific Integrity, Business Viability, and Patient Outcomes

As psychedelic therapies transition to mainstream medicine, organisations must navigate a complex trifecta: scientific integrity, business sustainability, and patient wellbeing. Drawing on our experience as a UK-based contract research organisation, this talk explores the balancing act required to thrive in this field. We’ll examine the ethical and operational challenges of designing trials that uphold rigorous scientific standards while addressing the financial pressures of a nascent industry. Strategies for keeping patient outcomes central to decision-making will be highlighted, even as commercial demands grow. Finally, we’ll explore how to drive meaningful impact in a high-stakes, rapidly evolving industry.